Research Analysts Set Expectations for Zevra Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright lifted their Q1 2024 earnings estimates for shares of Zevra Therapeutics in a research report issued to clients and investors on Wednesday, April 3rd. HC Wainwright analyst O. Livnat now anticipates that the company will post earnings per share of ($0.46) for the quarter, up from their prior forecast of ($0.47). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Zevra Therapeutics' Q2 2024 earnings at ($0.44) EPS, Q3 2024 earnings at ($0.45) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.55) EPS, FY2026 earnings at $1.55 EPS and FY2027 earnings at $2.64 EPS.

A number of other research analysts have also weighed in on ZVRA. Cantor Fitzgerald reissued an "overweight" rating on shares of Zevra Therapeutics in a report on Monday. Maxim Group raised their target price on shares of Zevra Therapeutics from $12.00 to $18.00 and gave the company a "buy" rating in a report on Tuesday. Finally, William Blair reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $19.50.

Zevra Therapeutics Price Performance

Shares of ZVRA stock traded down $0.09 on Friday, reaching $4.82. The company's stock had a trading volume of 192,240 shares, compared to its average volume of 259,401. The stock's fifty day simple moving average is $6.09 and its 200-day simple moving average is $5.37. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $7.28. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $209.33 million, a price-to-earnings ratio of -3.74 and a beta of 1.81.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio lifted its position in shares of Zevra Therapeutics by 52.5% during the fourth quarter. Public Employees Retirement System of Ohio now owns 5,337 shares of the company's stock worth $35,000 after purchasing an additional 1,837 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Zevra Therapeutics by 555.0% during the fourth quarter. International Assets Investment Management LLC now owns 6,550 shares of the company's stock worth $43,000 after purchasing an additional 5,550 shares during the last quarter. VisionPoint Advisory Group LLC bought a new stake in shares of Zevra Therapeutics during the third quarter worth $33,000. California State Teachers Retirement System bought a new stake in shares of Zevra Therapeutics during the third quarter worth $36,000. Finally, Strs Ohio bought a new stake in shares of Zevra Therapeutics during the third quarter worth $37,000. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.